Trial Profile
A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Study of the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of HMPL-523
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Dec 2016
Price :
$35
*
At a glance
- Drugs Sovleplenib (Primary)
- Indications Autoimmune disorders; Rheumatoid arthritis
- Focus Adverse reactions; First in man
- Sponsors Hutchison MediPharma
- 06 Dec 2016 According to a Hutchison MediPharma media release, data from this trial was presented at the Annual Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals.
- 14 Nov 2016 Results published in the Chi Med Media Release
- 14 Nov 2016 Data from this trial will be presented at the Annual Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals as reported by a Chi Med media release.